Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Q2 FY2022 Earnings Presentation
31 slides from Genetic Technologies's earnings presentation, Jan 21, 2022
Slide 1: Quarterly Investor Presentation
For personal use only Quarterly Investor Presentation January 21, 2022 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: Notice: Forward looking statements
For personal use only Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they
Slide 3: Our Overview
Our Overview For personal use only 01 02 03 04 05 06 Our Vision & Brand Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Pillars Divisions Innovation 2021 Overview Expanded to over 40 EasyDNA – Execution a Pathways, Divisions and Executing through cutting Aligning our inte
Slide 4: Unlocking personalised preventative health
01: Unlocking personalised For personal use only preventative health Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone. We’re transforming the conversation. Transitioning from a
Slide 5: geneType's pillars reflect its commitment to personalised, preventative health
01: geneType’s pillars reflect its commitment to personalised, preventative health For personal use only Unequalled experience Leading integrated technology Scientific team leveraging their extensive research track The sophisticated integration of genomic and clinical risk record in breast and color
Slide 6: Results & Highlights Qtr. 2, 2021
01: Results & Highlights Qtr. 2, 2021 For personal use only • Cash receipts in 2QFY22 are +113% versus the prior quarter (1QFY22) to A$1.8 million Cash Receipts (A$'000) following the successful integration of EasyDNA in the quarter • Multi-Test technical validation complete and submitted to NATA1 a
Slide 7: Our 2021 Snapshot
01: Our 2021 Snapshot For personal use only Signed multi-year Focused on R&D collaborations and New Multi-test pathway to distribution agreement Innovation launch License and distribution agreement for COVID- African American Breast Cancer Research Collaboration with New Multi-test technical validat
Slide 8: Our Markets and Collaborators
02: Our Markets and Collaborators Genetype and EasyDNA Brands now available in more that 40 countries For personal use only United States Europe & UK Asia Australia & New Zealand (Inc. SEA, China and India) geneType® Polygenic Risk Score Commencing CE certification Commencing a scoping and Certifica
Slide 9: A strategy to own the personalised, preventative health testing market
02: A strategy to own the personalised, preventative health testing market For personal use only Brand Recognition and Advocacy Commercialization and Branding Thought leadership Sales & marketing Demonstrating our leadership by informing the conversation Core set of sales and marketing tactics and a
Slide 10: A cutting-edge geneType brand relaunched
02: A cutting-edge geneType brand relaunched For personal use only Digital Mobile Education 10
Slide 11: Core set of sales material to empower clinicians and consumers
02: Core set of sales material to empower clinicians and consumers For personal use only At-a-glance HCP brochure Guide Book Patient Management case studies guide Clinical Patient Summaries booklet Expert Clinic interviews poster 11
Slide 12: EasyDNA – Establishing our Lifestyle Division
03: EasyDNA – Establishing our Lifestyle Division For personal use only • Acquired EasyDNA in August 2021 for US$4 million • Current revenues of US$4.63 million through retail sales of its at- home DNA tests • Agreements with 12 laboratories in North America, AsiaPac and Europe • Showing good baseli
Slide 13: Our Pathways
04: Our Pathways For personal use only Direct to consumer testing (DTC) Consumer initiated testing (CIT) Medical – Business to Business (B2B) with no medical supervision with medical supervision Recent Acquisition Provides Genetic Launched US and Current products A execution plan Health Economic ann
Slide 14: Our Divisions
04: Our Divisions For personal use only Emerging divisions Pharmoco- Oncology Genetics & Taliaz NEW – Universal collection test kit BC, CRC, PC, Existing divisions Melanoma Companion diagnostics to support Multi Test Launch CVD Germline testing BRCA, Lynch (Heart Disease) Syndrome and IHD, AF Somati
Slide 15: Segmentation framework
04: Segmentation framework Brand, channel and testing categories For personal use only Consumer-initiated testing Directtotoconsumer Direct to consumerDirect consumer ± telehealth support HCP requested test COVID Health & Wellbeing - Nutrition Oncology – GT/EasyDNA Paternity Paternity Animal Test ca
Slide 16: Our Portfolio − Driving Growth
05: Our Portfolio − Driving Growth For personal use only ` ` Moderate CIT Platform in AUS and USA Revenue selling BRC and CRC CY 2021 Relaunched with IBX COVID Risk Test released Vitagene December for sale May 31, 2021 2021 Expanding into reimbursable space 100% Germline + PRS test for Commercially1
Slide 17: NEW: Covid Risk Test (US)
NEW: Covid Risk Test (US) https://genetype.com/for-individuals/covid-19 For personal use only The link goes directly to Vitagene landing page: https://vitagene.com/products/covi d-19-risk-test/ 17
Slide 18: Our Innovation - Multi Test
05: Our Innovation - Multi Test A companion diagnostic PRS to help identify risk of serious disease for up to 70% of Mortalities and Morbidities For personal use only Committed to continually invest in developing multi population testing solutions Phase 1 Launch 2 Oncology GeneType Multi-test to inc
Slide 19: Our Innovation - Multi Test
05: Our Innovation - Multi Test Phase 1 Launch Test reports – NATA Validation pack submitted For personal use only 19
Slide 20: Our Innovation – Integrated Polygenic risk
05: Our Innovation – Integrated Polygenic risk For personal use only geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk 1,2,3 Breast Cancer
Slide 21: Significant market opportunity
05: Significant market opportunity To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions For personal use only Guideline driven, reimbursable for inherited and non inherited disease Near Term Addressable Market GTG Target Market for BRCA Panel + Breast
Slide 22: Our Capability
06: Our Capability For personal use only Dedicated Innovation Hub Developing and capturing the next generation of innovation in genomics Marketing and Positioning Enhanced Sales and Distribution Creating a consumer and patient led infrastructure Capitalise on Licensing, JV and M&A opportunities for
Slide 23: For personal use only
For personal use only 01 02 03 04 05 06 Our Vision & Brand Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Pillars Divisions Innovation Targeted and deliberate Positioned for Focused and Cutting edge Aligned to growth distinct innovation execute 23
Slide 24: Thank you
For personal use only Thank you Investor Relations and Media (US) Investor Relations - AUS Dave Gentry Stephanie Ottens Red Chip Market Eye Cell: +1 407 491 4498 +61 434 405 400 1 800 RED CHIP (733 2447) stephanie.ottens@marketeye.com.au dave@redchip.com
Slide 25: Appendices
For personal use only Appendices
Slide 26: Our Intellectual Property
Our Intellectual Property For personal use only 7 Patents granted in the US 9 Patent families pending • Patent 11,031,098, Computer systems and methods for genomic analysis • Methods for breast cancer risk assessment • Patent 10,683,549, Methods for assessing risk of developing breast cancer • Metho
Slide 27: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Executive Non – Executive Director FGIA, FTIA, F Fin Director Non – Executive Director Dr. Jerzy “George
Slide 28: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MWGO is Principal MD, MS, FACMG Research & Education Lead, Primary Care Fellow and Professor, Department of Me
Slide 29: Financial Overview
Financial Overview For personal use only • Cash burn of A$2.2 million in Q2 FY’22 (compared to Q1 FY’22: A$1.9 million) as we continue to grow EasyDNA brand sales and develop and commercialize our geneType tests A$’000 30 Sep 2021 31 Dec 2021 Change • Cash reserves of A$13.5 million after EasyDNA ac
Slide 30: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 20 January 2022 0.5c Other, 22% ADR price (USD) as at 20 January 2022 $2.08 Ord Shares on Issue (M) 9,234 Board & ASX 52-week trading (AUD low/high
Slide 31: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score
Genetic Technologies — Q2 FY2022 Earnings Presentation on 6ix